Page last updated: 2024-11-06

rimcazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

rimcazole: RN given refers to (cis)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID53389
CHEMBL ID275707
CHEBI ID94713
SCHEMBL ID99084
MeSH IDM0107345

Synonyms (41)

Synonym
bw-234u
tocris-1497
NCGC00025187-01
rimcazole
rimcazolum [inn-latin]
rimcazole [inn]
9h-carbazole, 9-(3-(3,5-dimethyl-1-piperazinyl)propyl)-, cis-
rimcazol [inn-spanish]
bw 234u
CHEMBL275707 ,
9-[3-[(3r,5s)-3,5-dimethylpiperazin-1-yl]propyl]carbazole
9-[3-((3s,5r)-3,5-dimethyl-piperazin-1-yl)-propyl]-9h-carbazole
9-[3-((3r,5r)-3,5-dimethyl-piperazin-1-yl)-propyl]-9h-carbazole
9-[3-((3r,5s)-3,5-dimethyl-piperazin-1-yl)-propyl]-9h-carbazole
9-[3-(3,5-dimethyl-piperazin-1-yl)-propyl]-9h-carbazole (rimcazole) (bw234u)
9-(3-((3s,5r)-3,5-dimethylpiperazin-1-yl)propyl)-9h-carbazole
bdbm50019742
9-[3-[(3s,5r)-3,5-dimethylpiperazin-1-yl]propyl]carbazole
rimcazolum
unii-c3n1ps8cx1
75859-04-0
rimcazol
c3n1ps8cx1 ,
9-(3-(cis-3,5-dimethyl-1-piperazinyl)propyl)carbazole
9h-carbazole, 9-(3-((3r,5s)-3,5-dimethyl-1-piperazinyl)propyl)-, rel-
SCHEMBL99084
9-[3-(3,5-cis-dimethylpiperazino)propyl]carbazole
9-[3-(3,5-cis-dimethylpiperazino)-propyl]-carbazole
9-[3-(3,5-cis-dimethylpiperazino)propyl]-carbazole
GUDVQJXODNJRIJ-CALCHBBNSA-N
cis-9-[3-(3,5-dimethyl-1-piperazinyl)propyl]carbazole
DTXSID7048162
CHEBI:94713
9-{3-[(3r,5s)-3,5-dimethylpiperazin-1-yl]propyl}-9h-carbazole
9-[3-[cis-3,5-dimethylpiperazin-1-yl]propyl]carbazole
Q7334422
9-[3-(3,5-dimethylpiperazin-1-yl)propyl]carbazole,hydrochloride
95586-99-5
EX-A5687
BR177827
AKOS040746287

Research Excerpts

Overview

Rimcazole is a carbazole derivative that acts in part as a sigma receptor antagonist. In open-clinical trials appears to be effective in acute schizophrenic patients.

ExcerptReferenceRelevance
"Rimcazole is a carbazole derivative that acts in part as a sigma receptor antagonist. "( Review of the pharmacological and clinical profile of rimcazole.
Gilmore, DL; Liu, Y; Matsumoto, RR, 2004
)
2.01
"Rimcazole (BW 234U) is a potential antipsychotic agent which in open-clinical trials appears to be effective in acute schizophrenic patients. "( Evidence that the potential antipsychotic agent rimcazole (BW 234U) is a specific, competitive antagonist of sigma sites in brain.
Chang, KJ; Ferris, RM; Russell, A; Tang, FL, 1986
)
1.97

Treatment

ExcerptReferenceRelevance
"Rimcazole treatment resulted in a greater than 4-fold reduction of tumor weight in comparison to controls at day 14 (100 ± 26 vs. "( In vivo responses of human A375M melanoma to a σ ligand: 18F-FDG PET imaging.
de Bruyn, M; de Jong, JR; Dierckx, RA; Elsinga, PH; Helfrich, W; Ramakrishnan, NK; Rybczynska, AA; van Waarde, A, 2013
)
1.83

Compound-Compound Interactions

ExcerptReferenceRelevance
" In addition, we aimed to explore differences in drug-drug interactions across multiple GBM-derived cell cultures and predict such differences by use of transcriptional biomarkers."( Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions.
Baskaran, S; Forsberg Nilsson, K; Gerlee, P; Häggblad, M; Hansson, C; Karlsson-Lindahl, L; Kling, T; Lundgren, B; Martens, U; Monsefi, N; Nelander, S; Olsson, M; Schmidt, L; Uhrbom, L; Westermark, B, 2013
)
0.39
"We performed a screen in which we quantified drug-drug interactions for 465 drug pairs in each of the 5 GBM cell lines U87MG, U343MG, U373MG, A172, and T98G."( Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions.
Baskaran, S; Forsberg Nilsson, K; Gerlee, P; Häggblad, M; Hansson, C; Karlsson-Lindahl, L; Kling, T; Lundgren, B; Martens, U; Monsefi, N; Nelander, S; Olsson, M; Schmidt, L; Uhrbom, L; Westermark, B, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
" In this study, BW234U, a selective but relatively weak sigma receptor antagonist was compared at two different dosage ranges with chlorpromazine and placebo in a double-blind randomized treatment trial in schizophrenic patients undergoing acute exacerbation."( Does sigma receptor antagonism predict clinical antipsychotic efficacy?
Borison, RL; Diamond, BI; Dren, AT, 1991
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
carbazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (48)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
15-lipoxygenase, partialHomo sapiens (human)Potency19.95260.012610.691788.5700AID887
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency15.84890.00207.533739.8107AID891
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency25.11890.316212.443531.6228AID902
cytochrome P450 2C19 precursorHomo sapiens (human)Potency3.16230.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency12.58930.00636.904339.8107AID883
huntingtin isoform 2Homo sapiens (human)Potency35.48130.000618.41981,122.0200AID1688
mitogen-activated protein kinase 1Homo sapiens (human)Potency39.81070.039816.784239.8107AID995
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency31.62280.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency21.13600.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency36.12540.005612.367736.1254AID624032
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency7.94330.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency12.58930.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sigma non-opioid intracellular receptor 1Mus musculus (house mouse)Ki0.82000.00190.20180.8200AID204597
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)IC50 (µMol)50.00000.00040.629810.0000AID4820
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)50.00000.00040.908610.0000AID4820
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)IC50 (µMol)0.14000.00070.97749.7000AID65154
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)Ki0.16440.00030.37088.1600AID65503; AID65638
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)IC50 (µMol)50.00000.00040.615610.0000AID4820
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)Ki1.26750.00000.705610.0000AID204541; AID204858
5-hydroxytryptamine receptor 2C Mus musculus (house mouse)Ki2.84200.00080.50322.8420AID5025
5-hydroxytryptamine receptor 2AMus musculus (house mouse)Ki2.84200.00080.65892.8420AID5025
D(3) dopamine receptorHomo sapiens (human)Ki8.00000.00000.602010.0000AID64978
D(2) dopamine receptorMus musculus (house mouse)IC50 (µMol)10.00000.00090.47332.4310AID61051
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki100.00000.00000.437510.0000AID65726
5-hydroxytryptamine receptor 2BMus musculus (house mouse)Ki2.84200.00080.65892.8420AID5025
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)IC50 (µMol)1.02350.00202.123310.0000AID317399; AID317400
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)Ki0.90800.00000.338510.0000AID1337349
Scavenger receptor class B member 1Homo sapiens (human)IC50 (µMol)1.20001.20001.20001.2000AID630155
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)0.91960.00030.70285.3660AID203852; AID204763; AID204792
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.90800.00000.490110.0000AID204630
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)1.41520.00030.55704.2000AID204605; AID204762; AID204763
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)Ki0.60500.00030.26715.0700AID1337349; AID204314
TransporterRattus norvegicus (Norway rat)Ki2.16000.00010.866710.0000AID145864; AID145885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histamine H2 receptorCavia porcellus (domestic guinea pig)K0.55.00000.00010.40364.8000AID88008
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (74)

Processvia Protein(s)Taxonomy
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
endothelial cell proliferationScavenger receptor class B member 1Homo sapiens (human)
cholesterol catabolic processScavenger receptor class B member 1Homo sapiens (human)
positive regulation of endothelial cell migrationScavenger receptor class B member 1Homo sapiens (human)
positive regulation of triglyceride biosynthetic processScavenger receptor class B member 1Homo sapiens (human)
positive regulation of cholesterol storageScavenger receptor class B member 1Homo sapiens (human)
regulation of phosphatidylcholine catabolic processScavenger receptor class B member 1Homo sapiens (human)
phospholipid transportScavenger receptor class B member 1Homo sapiens (human)
lipopolysaccharide transportScavenger receptor class B member 1Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayScavenger receptor class B member 1Homo sapiens (human)
detection of lipopolysaccharideScavenger receptor class B member 1Homo sapiens (human)
cholesterol effluxScavenger receptor class B member 1Homo sapiens (human)
high-density lipoprotein particle remodelingScavenger receptor class B member 1Homo sapiens (human)
low-density lipoprotein particle clearanceScavenger receptor class B member 1Homo sapiens (human)
high-density lipoprotein particle clearanceScavenger receptor class B member 1Homo sapiens (human)
vitamin transmembrane transportScavenger receptor class B member 1Homo sapiens (human)
wound healingScavenger receptor class B member 1Homo sapiens (human)
cholesterol homeostasisScavenger receptor class B member 1Homo sapiens (human)
blood vessel endothelial cell migrationScavenger receptor class B member 1Homo sapiens (human)
recognition of apoptotic cellScavenger receptor class B member 1Homo sapiens (human)
reverse cholesterol transportScavenger receptor class B member 1Homo sapiens (human)
adhesion of symbiont to hostScavenger receptor class B member 1Homo sapiens (human)
symbiont entry into host cellScavenger receptor class B member 1Homo sapiens (human)
carotenoid transportScavenger receptor class B member 1Homo sapiens (human)
regulation of phagocytosisScavenger receptor class B member 1Homo sapiens (human)
positive regulation of nitric-oxide synthase activityScavenger receptor class B member 1Homo sapiens (human)
triglyceride homeostasisScavenger receptor class B member 1Homo sapiens (human)
cholesterol importScavenger receptor class B member 1Homo sapiens (human)
intestinal lipid absorptionScavenger receptor class B member 1Homo sapiens (human)
plasma lipoprotein particle clearanceScavenger receptor class B member 1Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
lipopolysaccharide bindingScavenger receptor class B member 1Homo sapiens (human)
amyloid-beta bindingScavenger receptor class B member 1Homo sapiens (human)
virus receptor activityScavenger receptor class B member 1Homo sapiens (human)
phosphatidylserine bindingScavenger receptor class B member 1Homo sapiens (human)
lipopolysaccharide immune receptor activityScavenger receptor class B member 1Homo sapiens (human)
scavenger receptor activityScavenger receptor class B member 1Homo sapiens (human)
protein bindingScavenger receptor class B member 1Homo sapiens (human)
1-phosphatidylinositol bindingScavenger receptor class B member 1Homo sapiens (human)
high-density lipoprotein particle bindingScavenger receptor class B member 1Homo sapiens (human)
low-density lipoprotein particle bindingScavenger receptor class B member 1Homo sapiens (human)
apolipoprotein bindingScavenger receptor class B member 1Homo sapiens (human)
apolipoprotein A-I bindingScavenger receptor class B member 1Homo sapiens (human)
high-density lipoprotein particle receptor activityScavenger receptor class B member 1Homo sapiens (human)
lipid bindingScavenger receptor class B member 1Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
lysosomeScavenger receptor class B member 1Homo sapiens (human)
lysosomal membraneScavenger receptor class B member 1Homo sapiens (human)
plasma membraneScavenger receptor class B member 1Homo sapiens (human)
caveolaScavenger receptor class B member 1Homo sapiens (human)
cell surfaceScavenger receptor class B member 1Homo sapiens (human)
endocytic vesicle membraneScavenger receptor class B member 1Homo sapiens (human)
intracellular membrane-bounded organelleScavenger receptor class B member 1Homo sapiens (human)
extracellular exosomeScavenger receptor class B member 1Homo sapiens (human)
cytoplasmScavenger receptor class B member 1Homo sapiens (human)
plasma membraneScavenger receptor class B member 1Homo sapiens (human)
caveolaScavenger receptor class B member 1Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (84)

Assay IDTitleYearJournalArticle
AID203852The compound was tested for affinity towards sigma-3 receptor1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Conformational analysis, pharmacophore identification, and comparative molecular field analysis of ligands for the neuromodulatory sigma 3 receptor.
AID348765Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membrane2008Bioorganic & medicinal chemistry letters, Oct-01, Volume: 18, Issue:19
Dual DAT/sigma1 receptor ligands based on 3-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-1-phenylpropan-1-ol.
AID65191Binding affinity against dopamine transporter was determined by the displacement of [3H]WIN-35428 radioligand in rat brain2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.
AID225345Ability to block the aggressive behavior caused by prolonged isolation in mouse1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Piperidinyltetralin sigma ligands.
AID234377Selectivity ratio of DAT to that of NET receptor2001Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24
[3-cis-3,5-Dimethyl-(1-piperazinyl)alkyl]-bis-(4'-fluorophenyl)amine analogues as novel probes for the dopamine transporter.
AID169442Potential antipsychotic activity was assessed by measuring the ability to block the conditioned avoidance response(CAR) in rats on oral administration; value may range from 30 to 621987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Antipsychotic activity of substituted gamma-carbolines.
AID1409613Selectivity ratio: ratio of AUC (viral infection %) of SARS-CoV-2 in the Vero E6 cell line compared to AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay.2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1337385Displacement of [3H]-DTG from sigma 2 receptor in Sprague-Dawley rat liver membranes after 120 mins by scintillation counting analysis2016European journal of medicinal chemistry, Nov-29, Volume: 124Synthesis and biological evaluation of new aryl-alkyl(alkenyl)-4-benzylpiperidines, novel Sigma Receptor (SR) modulators, as potential anticancer-agents.
AID233513Ratio for the binding affinities of dopamine transporter over serotonin transporter2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.
AID204314The compound was tested for binding affinity of Sigma opioid receptor type 2 in rat liver membranes using [3H]DTG ligand1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.
AID1409609Cytotoxicity of compound against Vero E6 cells by MTT assay.2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID214497Percent Inhibition of trypanothione reductase activity at 57 uM concentration1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
A virtual screening approach applied to the search for trypanothione reductase inhibitors.
AID204764Ratio of the binding affinities against Sigma receptor type 1 and Sigma receptor type 21995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines.
AID62740Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Piperidinyltetralin sigma ligands.
AID343385Inhibition of Trypanosoma cruzi recombinant trypanothione reductase at 85 uM2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors.
AID131403Oral potency tested by using anti-mescaline test1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID204771Binding affinity towards Sigma receptor type 2 in whole rat brain homogenates except cerebellum using radioligand ([3H]DTG) binding assay.1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines.
AID176760In vivo 5-HT2 antagonism of 5-HTP-induced head twitch in rat; Not tested1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Piperidinyltetralin sigma ligands.
AID176445Oral potency by using Anti aggression test1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID317399Displacement of [3H]pentazocine from sigma1 receptor in guinea pig membrane2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Synthesis and structure-activity relationships of N-(3-phenylpropyl)-N'-benzylpiperazines: Potent ligands for sigma1 and sigma2 receptors.
AID204462Binding affinity for sigma receptor of guinea pig whole brain using [3H]-SKF- 100047 radioligand1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Piperidinyltetralin sigma ligands.
AID204792Binding affinity was evaluated using [3H]pentazocine binding to sigma-1 receptor from guinea pig brain1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Isothiocyanate derivatives of 9-[3-(cis-3,5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole): irreversible ligands for the dopamine transporter.
AID1337349Displacement of [3H]-pentazocine from sigma 1 receptor in guinea pig brain cortical membrane after 120 mins by scintillation counting analysis2016European journal of medicinal chemistry, Nov-29, Volume: 124Synthesis and biological evaluation of new aryl-alkyl(alkenyl)-4-benzylpiperidines, novel Sigma Receptor (SR) modulators, as potential anticancer-agents.
AID317401Ratio of IC50 for sigma1 receptor in absence of phenytoin to in presence of phenytoin in guinea pig membrane2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Synthesis and structure-activity relationships of N-(3-phenylpropyl)-N'-benzylpiperazines: Potent ligands for sigma1 and sigma2 receptors.
AID204765Ratio of the binding affinities for sigma-1 and sigma 2 type receptors, ratio of IC501995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
AID348764Displacement of [3H]nisoxetine from NET in rat frontal cortex membrane2008Bioorganic & medicinal chemistry letters, Oct-01, Volume: 18, Issue:19
Dual DAT/sigma1 receptor ligands based on 3-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-1-phenylpropan-1-ol.
AID88008Displacement of [3H](-)-trans-H2-PAT from Guinea pig histamine H2 receptors.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Synthesis, evaluation, and comparative molecular field analysis of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H(1) receptors.
AID131404Oral potency tested using apomorphine induced climbing test1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID348762Displacement of [3H]WIN-35428 from DAT in rat striatum membrane2008Bioorganic & medicinal chemistry letters, Oct-01, Volume: 18, Issue:19
Dual DAT/sigma1 receptor ligands based on 3-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-1-phenylpropan-1-ol.
AID5011Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Piperidinyltetralin sigma ligands.
AID223173Effect on the sleeping time of mice anesthetized with halothane (treated group)2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID204630Binding affinity against Sigma receptor type 1 was determined by the displacement of [3H]pentazocine radioligand2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.
AID204597In vitro binding affinity for the mouse sigma opioid receptor1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID229193Inhibition of specific binding of [3H]NANM of sigma receptor in Guinea pig brain membranes1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Radiosynthesis, cerebral distribution, and binding of [125I]-1-(p-iodophenyl)-3-(1-adamantyl)guanidine, a ligand for sigma binding sites.
AID204541Binding affinity at Serotonin transporter using [3H]citalopram as radioligand from rat brain2001Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24
[3-cis-3,5-Dimethyl-(1-piperazinyl)alkyl]-bis-(4'-fluorophenyl)amine analogues as novel probes for the dopamine transporter.
AID317400Displacement of [3H]pentazocine from sigma1 receptor in guinea pig membrane in presence of phenytoin2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Synthesis and structure-activity relationships of N-(3-phenylpropyl)-N'-benzylpiperazines: Potent ligands for sigma1 and sigma2 receptors.
AID204772Binding affinity towards sigma receptor binding site 2 using [3H]DTG of whole rat brain homogenates except cerebellum1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
AID221402Tested for rate of horizontal activity during a 30-min period after administration of compound at a concentration of 100 mg/kg2001Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24
[3-cis-3,5-Dimethyl-(1-piperazinyl)alkyl]-bis-(4'-fluorophenyl)amine analogues as novel probes for the dopamine transporter.
AID204536Binding affinity against serotonin transporter by displacement of [3H]citalopram in rat brain2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.
AID204858Binding affinity against Serotonin transporter in male Sprague-Dawley rats using [3H]paroxetine ligand1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.
AID4820In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Antipsychotic activity of substituted gamma-carbolines.
AID234372Selectivity ratio for DAT to SERT evaluated2001Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24
[3-cis-3,5-Dimethyl-(1-piperazinyl)alkyl]-bis-(4'-fluorophenyl)amine analogues as novel probes for the dopamine transporter.
AID223176Effect on the sleeping time of mice before halothane load (control group)2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID23920Partition coefficient value was determined from the ratio of ACD/LogD2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.
AID222711Effect on recovery time for coma induced in mice by cerebral concussion (control group)2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID229187Inhibition of specific binding of [125I]PIPAG to sigma receptor in Guinea pig brain membranes1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Radiosynthesis, cerebral distribution, and binding of [125I]-1-(p-iodophenyl)-3-(1-adamantyl)guanidine, a ligand for sigma binding sites.
AID204936Binding affinity was evaluated using [3H]-DTG binding to sigma-2 receptor from rat liver1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Isothiocyanate derivatives of 9-[3-(cis-3,5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole): irreversible ligands for the dopamine transporter.
AID214496Percent Inhibition of trypanothione reductase activity at 5.7 uM concentration1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
A virtual screening approach applied to the search for trypanothione reductase inhibitors.
AID64978Binding affinity at dopamine receptor D32001Journal of medicinal chemistry, Sep-13, Volume: 44, Issue:19
Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype.
AID65638Binding affinity to dopamine transporter (DAT) using [3H]WIN-35428 as a radioligand2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
2D QSAR modeling and preliminary database searching for dopamine transporter inhibitors using genetic algorithm variable selection of Molconn Z descriptors.
AID348766Selectivity ratio of Ki for rat brain stem SERT to Ki for rat striatum DAT2008Bioorganic & medicinal chemistry letters, Oct-01, Volume: 18, Issue:19
Dual DAT/sigma1 receptor ligands based on 3-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-1-phenylpropan-1-ol.
AID145885The compound was tested for binding affinity nisoxatine ligand1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.
AID229191Inhibition of specific binding of [3H]DTG to sigma receptor in Guinea pig brain membranes1992Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25
Radiosynthesis, cerebral distribution, and binding of [125I]-1-(p-iodophenyl)-3-(1-adamantyl)guanidine, a ligand for sigma binding sites.
AID222712Effect on recovery time for coma induced in mice by cerebral concussion (treated group)2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID221405Tested for rate of horizontal activity during a 30-min period after administration of compound at a concentration of 3 mg/kg2001Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24
[3-cis-3,5-Dimethyl-(1-piperazinyl)alkyl]-bis-(4'-fluorophenyl)amine analogues as novel probes for the dopamine transporter.
AID214495Percent Inhibition of trypanothione reductase activity at 28.5 uM concentration1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
A virtual screening approach applied to the search for trypanothione reductase inhibitors.
AID65154Inhibition of Dopamine uptake in male Sprague-Dawley rats using [3H]DA ligand1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.
AID630155Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human 293T cells by immunoblotting2011Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22
Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors.
AID65319Binding affinity at Dopamine transporter by displacing [3H]WIN-35428 from rat caudate putamen2001Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24
[3-cis-3,5-Dimethyl-(1-piperazinyl)alkyl]-bis-(4'-fluorophenyl)amine analogues as novel probes for the dopamine transporter.
AID1409608AUC (viral infection %) for SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells).2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID64286In vitro Dopamine receptor D2 affinity by using [3H]spiperone as the radioligand in rat limbic system at 1 uM concentration of compound.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Antipsychotic activity of substituted gamma-carbolines.
AID221403Tested for rate of horizontal activity during a 30-min period after administration of compound at a concentration of 10 mg/kg2001Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24
[3-cis-3,5-Dimethyl-(1-piperazinyl)alkyl]-bis-(4'-fluorophenyl)amine analogues as novel probes for the dopamine transporter.
AID5025In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID221404Tested for rate of horizontal activity during a 30-min period after administration of compound at a concentration of 30 mg/kg2001Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24
[3-cis-3,5-Dimethyl-(1-piperazinyl)alkyl]-bis-(4'-fluorophenyl)amine analogues as novel probes for the dopamine transporter.
AID64696Binding affinity was evaluated using [3H]WIN-35428 binding to dopamine transporter (DAT) in rat caudate-putamen1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Isothiocyanate derivatives of 9-[3-(cis-3,5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole): irreversible ligands for the dopamine transporter.
AID65726In vitro binding affinity for dopamine receptor D2 of rat nucleus accumbens labeled with [3H]spiperone1987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Psychotropic agents: synthesis and antipsychotic activity of substituted beta-carbolines.
AID147741Displacement of [3H]nisoxetine from rat brain norepinephrine transporter2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.
AID61051In vitro binding affinity towards dopamine receptor D21992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Novel piperidine sigma receptor ligands as potential antipsychotic drugs.
AID348768Selectivity ratio of Ki for rat brain stem SERT to Ki for guinea pig brain sigma 1 receptor2008Bioorganic & medicinal chemistry letters, Oct-01, Volume: 18, Issue:19
Dual DAT/sigma1 receptor ligands based on 3-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-1-phenylpropan-1-ol.
AID169418Antipsychotic activity was assessed by ability to block response of rats trained to avoid an electrical shock (inhibition of self-jump and/or discrete trial conditioned avoidance response(CAR) upon ip administration; value ranges from 30-621987Journal of medicinal chemistry, Jun, Volume: 30, Issue:6
Psychotropic agents: synthesis and antipsychotic activity of substituted beta-carbolines.
AID204762Compound was evaluated for the binding affinity towards Sigma receptor type 1 using radioligand ([3H]-(+)- Pentazocine) binding assay.1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines.
AID232102Ratio of binding affinities for dopamine and norepinephrine transporters2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.
AID204605Binding affinity for sigma receptor was evaluated by the inhibitory effect on [3H]DTG to rat whole brain membranes2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID348763Displacement of [3H]citalopram from SERT in rat brain stem membrane2008Bioorganic & medicinal chemistry letters, Oct-01, Volume: 18, Issue:19
Dual DAT/sigma1 receptor ligands based on 3-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-1-phenylpropan-1-ol.
AID1409607IC50 for antiviral activity against SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells).2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID204763Binding affinity towards sigma receptor binding site 1 using [3H](+)-pentazocine1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
AID145864Binding affinity at norepinephrine transporter using [3H]nisoxetine as radioligand from rat brain2001Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24
[3-cis-3,5-Dimethyl-(1-piperazinyl)alkyl]-bis-(4'-fluorophenyl)amine analogues as novel probes for the dopamine transporter.
AID204163Binding affinity of Sigma opioid receptor type 1 in Guinea pig brain membranes using [3H]pentazocine ligand1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.
AID1409611AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay.2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID232104Ratio of binding affinities for dopamine transporter over sigma-1 receptor2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.
AID65503Binding affinity Sprague-Dawley rats using [3H]WIN-35428 ligand1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.
AID225350Antimescaline activity in the mouse (administered po)1994Journal of medicinal chemistry, Feb-04, Volume: 37, Issue:3
Piperidinyltetralin sigma ligands.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (100)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (19.00)18.7374
1990's45 (45.00)18.2507
2000's23 (23.00)29.6817
2010's12 (12.00)24.3611
2020's1 (1.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.51 (24.57)
Research Supply Index4.66 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.94%)5.53%
Reviews4 (3.88%)6.00%
Case Studies1 (0.97%)4.05%
Observational0 (0.00%)0.25%
Other96 (93.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]